If you have been reading about freeze-thaw cycle and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-01-15. Where a claim depends on a specific study, the study is described rather than over-claimed.
Peptides are susceptible to hydrolysis, oxidation, and aggregation, and BPC-157 is no exception. The lyophilized powder form is generally more stable than a solution because residual moisture is low and molecular mobility is reduced. Once dissolved, the peptide is exposed to water, oxygen, and trace metal ions that accelerate degradation. Light exposure and repeated freeze-thaw cycles are also commonly cited as sources of loss. These general principles guide most handling recommendations found in supplier documentation.
Standard practice for the solid form is storage at minus twenty degrees Celsius or colder, kept dry and away from light. Containers are usually sealed with a desiccant to limit moisture uptake. Reconstituted solutions are typically held at two to eight degrees Celsius and used within a short window, because potency can decline over days to weeks depending on the buffer and concentration. Freezing an already dissolved sample may help, though repeated thawing is discouraged. Specific shelf-life claims vary between suppliers and are rarely supported by published stability studies.
Doses in the literature are usually expressed in micrograms or nanograms per kilogram of body weight. Investigators have administered the peptide by several routes, including injection and oral delivery, depending on the question asked. Route and dose vary widely across studies, which complicates direct comparison of results. Many papers report effects at low doses, but the absence of a standardized protocol limits generalization. Reporting practice differs between research groups.
Some properties, such as the peptide's sequence and molecular mass, are firmly established. Other claims, particularly about mechanism and clinical benefit, remain open questions. Proposed mechanisms include effects on nitric oxide signaling and on cell migration, but these are hypotheses supported by limited evidence. Reviewers often note that the field lacks large controlled human trials. Positive animal findings are best treated as signals for further study rather than as settled conclusions.
Most published studies examine BPC-157 in animal models rather than in humans. Common subjects include rats and mice, and researchers often use models of tissue injury, surgery, or induced inflammation. Reported endpoints include healing rates, blood vessel formation, and markers of tissue repair. These designs provide controlled comparisons, but findings in animals do not automatically transfer to people. Human clinical data remain limited and are frequently described as preliminary.
| Property | Value | Notes |
|---|---|---|
| Lyophilized powder storage | -20 C or colder, desiccated, protected from light | Long-term condition cited in supplier documentation |
| Reconstituted solution storage | 2-8 C for short-term use | Stability decreases after dissolution |
| Appearance | White to off-white lyophilized powder | Used as a visual identity check |
| Solubility | Soluble in water and aqueous buffers | Limited solubility in nonpolar organic solvents |
| Typical analytical method | Reversed-phase HPLC with UV detection at 214 nm | Purity estimate; mass spectrometry confirms molecular mass |
Analytical results depend on the column, gradient, and detector wavelength chosen by the laboratory, so purity values from different sources are not always directly comparable. Water content, counterion form, and residual trifluoroacetate affect both mass and purity calculations. Microbiological and endotoxin testing are separate from chemical purity and are not covered by a standard chromatographic run. Buyers evaluating a material typically request the full method description rather than a single purity figure.
Lyophilized peptide powder is generally stored at minus twenty degrees Celsius or lower and kept away from light and moisture. Under these conditions degradation is slow, and sealed vials remain stable for extended periods. Once dissolved, the material is less stable, particularly in aqueous buffers near neutral pH, where hydrolysis and oxidation proceed faster. Solutions are usually kept cold and used within days to weeks. Repeated freeze-thaw cycles are avoided because they encourage aggregation.
Identity and purity are established using reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities and yields a percentage purity. Mass spectrometry, typically with electrospray ionization, confirms the molecular mass against the expected value. Amino acid analysis or peptide mapping provides additional sequence confirmation. These methods are complementary, since chromatography measures how much material is present while mass spectrometry verifies what that material is. A certificate of analysis normally reports both.
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
Common synonyms in catalogs include pentadecapeptide BPC 157, BPC157, and the full sequence name. A CAS registry number in the 137525-51-0 range is frequently listed, though the assignment should be verified against the supplier certificate of analysis. The name itself is not a pharmacopoeial designation, and there is no standardized international nonproprietary name. Distinguishing genuine material from related fragments generally requires mass spectrometry, since several truncated sequences share similar chromatographic behavior.
BPC-157 is a synthetic pentadecapeptide whose sequence is commonly given as Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is described in the literature as a fragment of a larger protein found in human gastric juice, referred to as body protection compound. The peptide was first characterized in the early 1990s by a research group in Zagreb, Croatia. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Identity and purity are established with complementary methods rather than one test. Reverse-phase high-performance liquid chromatography separates the main peak from deletion sequences and oxidized variants, and its area percentage is the usual purity figure. Mass spectrometry confirms the expected molecular mass and can flag truncations or modifications that chromatography alone might miss. Amino acid analysis and peptide mapping add sequence-level confirmation, while residual counter-ion and water content are measured separately.
A freeze-dried sample is generally the most stable form and is commonly held at minus twenty degrees Celsius or lower for long-term keeping, with brief transfers at room temperature. The solid is hygroscopic, so vials are warmed to ambient temperature before opening to prevent condensation from degrading the contents. Light exposure and repeated temperature cycling are both avoided in routine handling. Storage over a desiccant is a common laboratory practice that limits moisture uptake during repeated access.
=== Composition and selectivity === Condensate components are usually divided into scaffolds, which drive phase separation, and clients, which do not phase separate on their own but can still be recruited into the dense phase. Client recruitment depends on the number of available binding sites as well as the valency and affinity of the client, so changes in scaffold stoichiometry can alter the composition of the condensate. Partitioning is also influenced by physical factors that are distinct from specific binding. Because condensates consist of dense networks of intrinsically disordered regions (IDRs), inserting a molecule restricts the conformational freedom of the surrounding chains, resulting in an entropic penalty that increases with particle size. Calculations combined with coarse-grained modelling show that the free energy of insertion increases with both IDR density and particle size, and becomes dependent on particle surface area once the particle is larger than the network mesh size. At typical IDR concentrations, particles as small as 4 nm in diameter can be almost entirely excluded, with approximately 97% exclusion in the absence of favourable interactions with condensate components.
=== Negative feedback === Thrombin bound to thrombomodulin activates protein C, an inhibitor of the coagulation cascade. The activation of protein C is greatly enhanced following the binding of thrombin to thrombomodulin, an integral membrane protein expressed by endothelial cells. Activated protein C inactivates factors Va and VIIIa. Binding of activated protein C to protein S leads to a modest increase in its activity. Thrombin is also inactivated by antithrombin, a serine protease inhibitor.
Bush released his memoirs, Decision Points, on November 9, 2010. During a pre-release appearance promoting the book, Bush said he considered his biggest accomplishment to be keeping "the country safe amid a real danger", and his greatest failure to be his inability to secure the passage of Social Security reform. He also made news defending his administration's enhanced interrogation techniques, specifically the waterboarding of Khalid Sheikh Mohammed, saying, "I'd do it again to save lives." In 2012, he wrote the foreword to The 4% Solution: Unleashing the Economic Growth America Needs, an economics book published by the George W. Bush Presidential Center. He also presented the book at the Parkland Memorial Hospital in Dallas, Texas. Bush did not physically appear in that year's Republican National Convention (where Mitt Romney obtained the party's nomination for president), instead appearing in a videotape, in which he –alongside his father and immediate family– explained his reasons for supporting Romney. Bush appeared on NBC's The Tonight Show with Jay Leno on November 19, 2013, along with his wife Laura. When asked by Leno why he does not comment publicly about the Obama administration, Bush said: "I don't think it's good for the country to have a former president criticize his successor." Despite this statement, Bush vocally disagreed with Obama's withdrawal of U.S. troops from Iraq in 2011, calling it a "strategic blunder". In December, Bush traveled with President Obama to the memorial service of South African president and civil rights leader Nelson Mandela.
==== Anesthesia awareness ==== Thiopental is a rapid and effective drug for inducing unconsciousness, since it causes loss of consciousness upon a single circulation through the brain due to its high lipophilicity. Only a few other drugs, such as methohexital, etomidate, or propofol, have the capability to induce anesthesia so rapidly. (Narcotics such as fentanyl are inadequate as induction agents for anesthesia.) Supporters argue that since the thiopental is given at a much higher dose than for medically induced coma protocols, it is effectively impossible for the condemned to wake up. Anesthesia awareness occurs when general anesthesia is inadequately maintained, for a number of reasons. Typically, anesthesia is 'induced' with an intravenous drug but 'maintained' with an inhaled anesthetic given by the anesthesiologist or nurse-anesthetist (note that there are several other methods for safely and effectively maintaining anesthesia). Barbiturates are used only for induction of anesthesia, and although these drugs rapidly and reliably induce anesthesia, they wear off quickly. A neuromuscular-blocking drug may then be given to cause paralysis, which facilitates intubation, although this is not always required. The anesthesiologist or nurse anesthetist is responsible for ensuring that the maintenance technique (typically inhalational) is started soon after induction to prevent the patient from waking up. General anesthesia is not maintained with barbiturate drugs because they are so short-acting.
Sources: en.wikipedia.org
The first nonsteroidal androgens, the arylpropionamides, were discovered via structural modification of bicalutamide. Unlike bicalutamide (which is purely antiandrogenic), these compounds show tissue-selective androgenic effects and were classified as selective androgen receptor modulators (SARMs). Lead SARMs of this series included acetothiolutamide, enobosarm (ostarine; S-22), and andarine (acetamidoxolutamide or androxolutamide; S-4). They are very close to bicalutamide structurally, with the key differences being that the linker sulfone of bicalutamide has been replaced with an ether or thioether group to confer agonism of the AR and the 4-fluoro atom of the pertinent phenyl ring has been substituted with an acetamido or cyano group to eliminate reactivity at the position.
== Adverse effects == Side effects are rare. Reported adverse events include seizures, changes in color vision, blood clots, and allergic reactions such as anaphylaxis. Whether the risk of venous thromboembolism (blood clots) is increased is a matter of debate. The risk is mentioned in the product literature, and they were reported in post marketing experience. Despite this, and the inhibitory effect of tranexamic acid on blood clot breakdown, large studies of the use of tranexamic acid have not shown an increase in the risk of venous or arterial thrombosis, even in people who had previously experienced thrombosis under other circumstances.
(This formula is used for example in describing the measuring principle of a dasymeter and of hydrostatic weighing.) Example: If you drop wood into water, buoyancy will keep it afloat. Example: A helium balloon in a moving car. When increasing speed or driving in a curve, the air moves in the opposite direction to the car's acceleration. However, due to buoyancy, the balloon is pushed "out of the way" by the air and will drift in the same direction as the car's acceleration. When an object is immersed in a liquid, the liquid exerts an upward force, which is known as the buoyant force, that is proportional to the weight of the displaced liquid. Consequently, the net force acting on the object is equal to the difference between the weight of the object, or 'down' force, and the weight of the displaced fluid, or 'up' force. Equilibrium, or neutral buoyancy, is achieved when these two weights and thus forces are equal.
=== Processing issues and solutions === Nanocapsules tend to aggregate and become unstable. Thus, substances within capsules can leak. To control the instability, nanocapsules can be dried either through spray drying or freeze-drying (lyophilization). Spray drying – Solutions are sprayed into a drying medium. This method is more widely used in the food industry and used for encapsulation of many food products as flavors, minerals, colors, and vitamins. This method makes nanocapsules more stable, and increases shelf-life of foods. Freeze-drying – This process involves dehydration of materials that are heat-sensitive. Unlike spray drying, water is removed through the sublimation process without changing the structure or shape of the nanoparticles. Freeze-drying involves four states: freezing, primary drying, secondary drying, and storage. Because of the multiple stages involved, this method is considered to demand more energy and time.
In the early 1990s, an ALZA-funded research program began to develop a new dosage form of methylphenidate for the treatment of children with attention deficit hyperactivity disorder (ADHD). Methylphenidate's short half-life required multiple doses to be administered each day to attain long-lasting coverage, which made it an ideal candidate for the OROS technology. Multiple candidate pharmacokinetic profiles were evaluated and tested in an attempt to determine the optimal way to deliver the drug, which was especially important given the puzzling failure of an existing extended-release formulation of methylphenidate (Ritalin SR) to act as expected. The zero-order (flat) release profile that the PPOP was optimal at delivering failed to maintain its efficacy over time, which suggested that acute tolerance to methylphenidate formed over the course of the day. This explained why Ritalin SR was inferior to twice-daily Ritalin IR, and led to the hypothesis that an ascending pattern of drug delivery was necessary to maintain clinical effect. Trials designed to test this hypothesis were successful, and ALZA subsequently developed a modified PPOP design that utilized an overcoat of methylphenidate designed to release immediately and rapidly raise serum levels, followed by 10 hours of first-order (ascending) drug delivery from the modified PPOP design. This design was called the Push-Stick Osmotic Pump (PSOP), and utilized two separate drug layers with different concentrations of methylphenidate in addition to the (now quite robust) push layer.
Sources: en.wikipedia.org
== Function == The protein encoded by this gene is a noncollagenous extracellular matrix (ECM) protein. It consists of five identical glycoprotein subunits, each with EGF-like and calcium-binding (thrombospondin-like) domains. Oligomerization results from formation of a five-stranded coiled coil and disulfide bonds. Binding to other ECM proteins such as collagen appears to depend on divalent cations. Mutations can cause the osteochondrodysplasias pseudoachondroplasia (PSACH) and multiple epiphyseal dysplasia (MED). COMP is a marker of cartilage turnover. It is present in high quantities in fibrotic scars and systemic sclerosis, and it appears to have a role in vascular wall remodeling.
acid dissociation constant (Ka) Also acid ionization constant or acidity constant. A quantitative measure of the strength of an acid in solution expressed as an equilibrium constant for a chemical dissociation reaction in the context of acid-base reactions. It is often given as its base-10 cologarithm, pKa.
=== Evolved suicidal action of OmpT === In zebrafish, ZF-RNase-3 (A5HAK0) must be cleaved by a protease (such as OmpT) in order to become activated and serve its bactericidal function. Through this evolved suicidal mechanism, the RNase mediates its own activation, since it is only cleaved in the presence of its bacterial target.
=== Vertebrates === In birds, the trachea runs from the pharynx to the syrinx, from which the primary bronchi diverge. Swans have an unusually elongated trachea, part of which is coiled beneath the sternum; this may act as a resonator to amplify sound. In some birds, the tracheal rings are complete, and may even be ossified. In amphibians, the trachea is normally extremely short, and leads directly into the lungs, without clear primary bronchi. A longer trachea is, however, found in some long-necked salamanders, and in caecilians. While there are irregular cartilagenous nodules on the amphibian trachea, these do not form the rings found in amniotes. The only vertebrates to have lungs, but no trachea, are the lungfish and the Polypterus, in which the lungs arise directly from the pharynx.
Sources: en.wikipedia.org
Reversed-phase HPLC separates the sample into peaks, and the main peak is expressed as a percentage of total peak area. Mass spectrometry is then used to confirm that the molecular mass matches the expected value.
Low temperature and low moisture slow hydrolysis and oxidation, the two main degradation routes for short peptides. A desiccant limits water uptake each time the vial is opened.
No single number captures identity, counter-ion content, water content, or sterility. A purity figure from one laboratory method reflects only what that method detects, and different methods can give different values for the same sample.
Human data are limited. Most evidence comes from animal experiments and from small or uncontrolled reports. The absence of large trials means clinical effects and safety are not firmly established.